BeOne Medicines financials
$365.27−0.47%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 |
|---|---|---|---|---|---|---|
| Revenue | $1.71B | $1.51B | $1.50B | $1.41B | $1.32B | $1.12B |
| Gross profit | $1.53B | $1.35B | $1.36B | $1.22B | $1.15B | $952.3M |
| Gross margin | 89.8% | 89.0% | 90.5% | 86.1% | 87.5% | 85.2% |
| Operating income | $325.0M | $249.9M | $185.0M | $163.1M | $87.9M | $11.1M |
| Net income | $237.0M | $227.4M | $66.5M | $124.8M | $94.3M | $1.3M |
| Net margin | 13.9% | 15.0% | 4.4% | 8.8% | 7.2% | 0.1% |
| Diluted EPS | $0.16 | $0.15 | $0.04 | $0.08 | $0.06 | $0.00 |
| EBITDA | $365.6M | $291.0M | $221.0M | $200.4M | $123.5M | $43.9M |
| Operating cash flow | $462.8M | $201.3M | $417.3M | $402.6M | $263.6M | $44.1M |
| Free cash flow | $435.3M | $160.5M | $379.8M | $293.8M | $247.4M | -$72.3M |
| Diluted shares | 1,505.4M | 1,505.0M | 1,502.0M | 1,488.8M | 1,463.3M | 1,445.3M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $5.10B | $4.79B | $4.55B | $4.04B | $2.76B | $2.52B |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $1.07B | $1.08B | $1.02B | $1.84B | $954.5M | $923.6M |
| Total assets | $9.18B | $8.55B | $8.19B | $7.63B | $6.30B | $5.84B |
| Total liabilities | $4.00B | $3.79B | $3.83B | $3.50B | $2.53B | $2.34B |
| Shareholders' equity | $5.17B | $4.76B | $4.36B | $4.13B | $3.77B | $3.50B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology